HC Wainwright Issues Optimistic Estimate for POAI Earnings

Predictive Oncology Inc. (NASDAQ:POAI) – Equities researchers at HC Wainwright increased their Q4 2025 earnings estimates for Predictive Oncology in a research note issued to investors on Friday, November 15th. HC Wainwright analyst S. Ramakanth now expects that the medical instruments supplier will earn $0.06 per share for the quarter, up from their previous estimate of $0.05. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Predictive Oncology’s current full-year earnings is ($2.03) per share. HC Wainwright also issued estimates for Predictive Oncology’s FY2026 earnings at $0.08 EPS, FY2027 earnings at $0.27 EPS and FY2028 earnings at $0.46 EPS.

Predictive Oncology Price Performance

Shares of NASDAQ POAI opened at $0.69 on Monday. Predictive Oncology has a one year low of $0.55 and a one year high of $3.76. The firm’s 50 day simple moving average is $0.75 and its two-hundred day simple moving average is $1.06. The stock has a market capitalization of $4.58 million, a P/E ratio of -0.23 and a beta of 1.14.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.